Icon Plc (ICLR)
NASDAQ:ICLR
ICLR Stock Chart & Stats
$106.81
-$3.85(-1.73%)
At close: 4:00 PM EST
$106.81
-$3.85(-1.73%)
Day’s Range― - ―
52-Week Range$66.57 - $211.00
Previous CloseN/A
Volume330.38K
Average Volume (3M)939.03K
Market Cap
$8.16B
Enterprise Value$11.26B
Total Cash (Recent Filing)$468.89M
Total Debt (Recent Filing)$3.57B
Price to Earnings (P/E)1437.4
Beta1.07
Next Earnings
Apr 29, 2026EPS Estimate
3.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.29
Shares Outstanding76,359,930
10 Day Avg. Volume705,667
30 Day Avg. Volume939,031
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)1.82
Price to Sales (P/S)2.09
P/FCF Ratio15.46
Enterprise Value/Market Cap1.38
Enterprise Value/Revenue1.39
Enterprise Value/Gross Profit5.18
Enterprise Value/Ebitda9.55
Forecast
1Y Price Target
$120.40Price Target Upside12.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)12.41
Revenue Forecast (FY)$7.92B
Bulls Say, Bears Say
Bulls Say
R&D Spending TailwindRevisions to large pharmaceutical clients' research and development budgets point to higher expected spending, which should boost demand for ICON's clinical trial services.
Valuation And Cash PositionManagement indicates the revenue recognition issues are limited in scope, cash balances are unaffected, and the company generates meaningful free cash flow, making valuation appear attractive relative to peers if the review is contained.
Wallet-share GainsData scrapes indicate ICON is gaining wallet share at multiple large pharmaceutical clients, supporting expectations for increased revenue and reinforcing competitive position.
Bears Say
Accounting Investigation UncertaintyA disclosed internal accounting review focused on revenue recognition creates uncertainty around reported results and adds downside risk until the review is resolved.
Credibility And Confidence GapThe combination of an accounting investigation, client losses, and concerns about artificial intelligence has damaged credibility with investors, depressing sentiment and valuation relative to peers.
Customer Cancellations And Margin PressureHigh customer cancellations and industry-wide margin pressures are reducing profitability and weighing on the company's outlook.
Icon News
ICLR FAQ
What was Icon Plc’s price range in the past 12 months?
Icon Plc lowest stock price was $66.57 and its highest was $211.00 in the past 12 months.
What is Icon Plc’s market cap?
Icon Plc’s market cap is $8.16B.
When is Icon Plc’s upcoming earnings report date?
Icon Plc’s upcoming earnings report date is Apr 29, 2026 which is in 15 days.
How were Icon Plc’s earnings last quarter?
Icon Plc released its earnings results on Feb 25, 2026. The company reported $3.29 earnings per share for the quarter, beating the consensus estimate of $3.209 by $0.081.
Is Icon Plc overvalued?
According to Wall Street analysts Icon Plc’s price is currently Undervalued.
Does Icon Plc pay dividends?
Icon Plc does not currently pay dividends.
What is Icon Plc’s EPS estimate?
Icon Plc’s EPS estimate is 3.02.
How many shares outstanding does Icon Plc have?
Icon Plc has 76,359,930 shares outstanding.
What happened to Icon Plc’s price movement after its last earnings report?
Icon Plc reported an EPS of $3.29 in its last earnings report, beating expectations of $3.209. Following the earnings report the stock price went down -2.969%.
Which hedge fund is a major shareholder of Icon Plc?
Currently, no hedge funds are holding shares in ICLR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Icon Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$120.40 (12.72% Upside)
$120.40 (12.72% Upside)
Blogger Sentiment
Bullish
ICLR Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 308.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $61.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.2%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
Icon Plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
ICLR Stock 12 Month Forecast
Average Price Target
$120.40
▲(12.72% Upside)
Technical Analysis
Ownership Overview
0.40% Insiders
36.10% Mutual Funds
53.08% Other Institutional Investors
8.30% Public Companies and
Individual Investors